Methadone reduces the need for antipsychotic and antimanic agents in heroin addicts hospitalized for manic and/or acute psychotic episodes

Heroin Addiction and Related Clinical Problems

Volumn 7, Issue 4, 2005, Pages 43-48

  Pacini, Matteo ^a,b   Maremmani, Icro ^a,b,c,d  

^a UNIVERSITY OF PISA   (Italy)

^b G De Lisio Istitute of Behavioural Sciences Pisa ^*  (Italy)

^c Association for the Application of Neuroscientific Knowledge to Social Aims   (Italy)

^d UNIVERSITY OF PISA   (Italy)

Author keywords

Anti manic Drugs; Antipsychotic Drugs; Dual Diagnosis; Methadone

Indexed keywords

DIAMORPHINE; METHADONE; NEUROLEPTIC AGENT; OPIATE; TRANQUILIZER;

ACUTE PSYCHOSIS; ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; DRUG ABUSE; DRUG EFFECT; FEMALE; HEROIN DEPENDENCE; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MANIA; METHADONE TREATMENT; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY;

EID: 30444441986     PISSN: 15921638     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. ABSE D. W., DAHSTROM W. G. (1960): The value of chemotherapy in senile mental disturbances: controlled comparison of chlorpromazine, reserpine-pipradol and opium. JAMA. 174 2036-2042.
2. BODKIN J. A., ZORNBERG G. L., LUKAS S. E., COLE J. O. (1995): Buprenorphine treatment of refractory depression. J Clin Psychopharmacol 15:(1) 49-57.
3. CARLSON E. T., SIMPSON M. M. (1963): Opium as a tranquilizer. Am J Psychiatry 120 112-117.
4. CHANG A. E., SHILING D. J., STILLMAN R. C., GOLDBERG N. H., SEIPP C. A., BAROFSKY I., SIMMON R. M., ROSENBERG S. A. (1979): Evaluation of antiemetic effects of delta-9-THC during adjuvant chemotherapy in patients receiving high dose therapy. Ann Intern Med. 91 825-837.
5. EMRICH H. M., GUNTHER R., DOSE M. (1983): Current perspectives in the pharmacopsychiatry of depression and mania. Neuropharmacology. 22:(3) 385-388.
6. EMRICH H. M., VOGT P., HERZ A. (1982): Possible antidepressive effects of opioids: action of buprenorphine. In: VEREBEY K. (Ed.) Opioids in mental illness: theories, clinical observations and treatment possibilities. Ann. N. Y. Acad. Vol. 398. The New York Academy of Sciences, New York, N. Y. pp.
7. EMRICH H. M., VOGT P., HERZ A., KISSLING W. (1982): Antidepressant effects of buprenorphine.. Lancet. 25:(2-8300) 709.
8. EXTEIN I., PICKAR D., GOLD M. S., GOLD P. W., POTTASH A. L., SWEENEY D. R., ROSS R. J., REBARD R., MARTIN D., GOODWIN F. K. (1981): Methadone and morphine in depression. Psychopharmacol Bull. 17:(1) 29-33.
9. EXTEIN I., PICKARD D., GOLD M. S., GOLD P. W., POTTASH A. L. C., SWEENEY D. R., ROSS R. J., REBARD R., MARTIN D., GOODWIN F. K. (1981): Methadone and morphine in depression. Pharmacol Bull. 17 29-33.
10. FINK M., SIMEON J., ITIL T. M., FREEDMAN A. M. (1970): Clinical antidepressant activity of cyclazocine-a narcotic antagonist. Clin Pharmacol Ther:(11) 41-48.
11. GOLD M. S., POTTASH A. C., SWEENEY D. R., KLEBER H. D., REDMOND E. (1979): Rapid opiate detoxification: clinical evidence of antidepressant and antpanic effects of opiates.. Am J Psychiatry:(136) 982-983.
12. GOLD M. S., POTTASH A. L. C., SWEENEY D. R., MARTIN D., EXTEIN I. (1982): Antimanic, antidepressant, and antipanic effects of opiate: clinical, neuro-anatomical, and biochemical evidence. In: VEREBEY K. (Ed.) Opioids in mental illness: theories, clinical observations and treatment possibilities. Ann. N. Y. Acad. V. 398. The New York Academy of Sciences New York, N. Y. pp.
13. LEHMANN H. E., ANANTH J. V., GEAGEA A., BAN T. A. (1971): Treatment of depression with dexedrine anddemerol. Cur Ther Res. 13:(1) 42-49.
14. LEVINSON I., ROSENTHAL R. N. (1995): Methadone withdrawal psychosis. J Clin Psychiatry. 56:(2) 73-76.
15. MAREMMANI I., CANONIERO S., PACINI M. (2000): Methadone dose and retention in treatment of heroin addicts with Bipolar I Disorder comorbidity. Preliminary Results. Heroin Add & Rel Clin Probl. 2:(1) 39-46.
16. MAREMMANI I., CANONIERO S., PACINI M., LOVRECIC M., TAGLIAMONTE A. (2001): An eigh year longitudinal study of psychiatric patients on methadone maintenance treatment. Odvisnosti. 2:(1-2) 22-24.
17. MAREMMANI I., MARINI G., FORNAI F. (1998): Naltrexone induced Panic Attacks. Am J Psychiatry. 155:(3) 447.
18. MAREMMANI I., PACINI M., GIUNTOLI G., LOVRECIC M., PERUGI G. (2004): Naltrexone as maintenance therapy for heroin addiction: Predictors of response. Heroin Add & Rel Clin Probl. 6:(1) 43-52.
19. MAREMMANI I., PACINI M., LUBRANO S., LOVRECIC M., PERUGI G. (2003): Dual diagnosis heroin addicts. The clinical and therapeutic aspects. Heroin Add & Rel Clin Probl. 5:(2) 7-98.
20. MAREMMANI I., ZOLESI O., AGLIETTI M., MARINI G., TAGLIAMONTE A., SHINDERMAN M. S., MAXWELL S. (2000): Methadone Dose and Retention in Treatment of Heroin Addicts with Axis I Psychiatric Comorbidity. J Addict Dis. 19:(2) 29-41.
21. MAREMMANI I., ZOLESI O., AGUECI T., CASTROGIOVANNI P. (1993): Methadone Doses and Psychopathological Symptoms during Methadone Maintenance. J Psychoactive Drugs. 25(3) 253-263.
22. MAREMMANI I., ZOLESI O., TAGLIAMONTE A. (1997): Methadone Treatment in West Europe. The Italian Paradigma. In: MAREMMANI I., REISINGER M. (Eds.): Methadone Treatment in Europe. Pacini Editore Medicina, Pisa. pp. 21-26.
23. MCKENNA G. J. (1973): The use of methadone as a psychotropic agent. Nat Conf Methadone Treat Proc. 5 1317-1324.
24. MCKENNA G. J. (1982): Methadone and opiate drugs: psychotropic effects and self medication. In: VEREBEY K. (Ed.) Opioids in Mental Illness. The New York Academy of Sciences, New York, NY. pp. 33-43.
25. PANI P. P., AGUS A., GESSA G. L. (1999): Methadone as a mood stabilizer [Letter]. Heroin Add & Rel Clin Probl. 1:(1) 43-44.
26. VARGA E., SUGERMAN A. A., APTER J. (1982): The effect of codeine on involutional and senile depression. In: VEREBEY K. (Ed.) Opioids in mental illness: theories, clinical observations and treatment possibilities. Ann. N. Y. Acad. V. 398. The New York Academy of Sciences, New York, N. Y. pp.
27. VEREBEY K. (1982): Opioids in mental illness: theories, clinical observations and treatment possibilities, The New York Academy of Sciences, New York, N. Y.